The National Agency for Food and Drug Administration and Control (NAFDAC) has reported a surge in foreign investment within Nigeria’s pharmaceutical industry after rolling out its 5+5 Policy, designed to advance domestic medicine manufacturing.
Launched in 2018 by Director-General Prof. Mojisola Adeyeye, the policy has spurred foreign companies to set up local factories and collaborate with Nigerian firms, enhancing production capabilities and cutting import dependency.
During a courtesy call in Abuja from Indonesian Ambassador to Nigeria, Ambassador Bambang Suharto, Prof. Adeyeye pointed out that Nigeria’s achievement of World Health Organization (WHO) Maturity Level 3, plus its 2025 recertification for overseeing medicines and vaccines, has bolstered investor trust.
She added that NAFDAC’s cutting-edge Biologics and Vaccines Laboratory in Lagos bolsters the nation’s regulatory and manufacturing strengths.
Prof. Adeyeye reiterated NAFDAC’s dedication to aiding investors via the 5+5 policy, which mandates a shift from imports to local production within a set period.
She stressed that the policy plays a key role in expanding access to high-quality drugs, fortifying medicine supply security, and fueling economic progress.
Ambassador Suharto praised NAFDAC’s direction and voiced Indonesia’s eagerness to expand ties via a Memorandum of Understanding (MoU) for better trade, knowledge sharing, and skill development.
